Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization.

Front Immunol · 2024 · PMC11683073 · PMID 39737197

Europe PMC DOI

hedged sentence

0.0558

closest p · 1.1× alpha

0.0558

boldest claim

The sentences

did not reach statistical significancep = 0.0558so close (0.05 < p ≤ 0.1)

The RBD-3M-052-Alum prime-boost regimen produced a mean response of ~0.6-log greater than the saRNA-NLC prime-boost regimen; however, this difference did not reach statistical significance ( p = 0.0558).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.